Replimune Group Inc (REPL)

$2.42 -0.43 (-15.09%)
Market Cap 235.33M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 8,854,400
Avg Vol 5,136,706
Day's Range N/A - N/A
Shares Out 82.57M
Stochastic %K 58%
Beta 0.74
Analysts Hold
Price Target $2.20

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
csliumanila
csliumanila Apr. 25 at 3:49 AM
$REPL "RP1 combined with nivolumab provided deep and durable systemic responses in patients with anti–PD-1–failed melanoma, including those with poor prognostic factors. The safety profile was favorable, with mostly grade 1/2 adverse events." "Tumor-infiltrating lymphocyte therapy (lifileucel) is the only US Food and Drug Administration (FDA)–approved therapy for melanoma in patients previously treated with anti–PD-1 therapy16,17 and provided an objective response rate (ORR) of 31.4%.18 However, nearly all patients experienced grade 3/4 treatment-emergent adverse events,18,19 and the treatment-related mortality rate was 7.5%." https://ascopubs.org/doi/10.1200/JCO-25-01346
0 · Reply
RoyalImperial
RoyalImperial Apr. 24 at 9:43 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $MSS $REPL $BLDP $FFAI ww..11
0 · Reply
GangsterX
GangsterX Apr. 24 at 8:47 PM
$PMVP $GERN $REPL still holding.. 3 biggies
0 · Reply
Spoook
Spoook Apr. 24 at 7:25 PM
$REPL tick…..tick….tick
0 · Reply
US_Bull
US_Bull Apr. 24 at 7:05 PM
$REPL They did the same bs pump after the first CRL remember the liquidity exit where it pumped close to 100% after first CRL and more crying. Retail is left holding the big tute bag
0 · Reply
US_Bull
US_Bull Apr. 24 at 7:02 PM
$REPL Feel bad for those naive retailers who didn't do their DD and listened to the blind bulls living on hopium. As I was saying 1.50$ is coming no time no path forward but to conduct whole new trials after a majorly failed trial design. More dilutions and secondaries to raise money and stay in business. This is one big pipe dream.
1 · Reply
TopCharts
TopCharts Apr. 24 at 6:52 PM
$REPL will be the next outlook therapeutics $2 then ultimately 30 cents. No revenue no approved real product no money.
1 · Reply
cowneck_trader
cowneck_trader Apr. 24 at 6:48 PM
$REPL CEO wamts to waste taxpayer dollars sueing the FDA just so he can get another 6 months of bloated salary. This charlatan needs to have his natualized citizenship revoked!
0 · Reply
USMAgrad
USMAgrad Apr. 24 at 6:43 PM
$REPL Disclaimer: I own 1 share of this stock just for shits-n-grins Just a couple thoughts in the face of the wild price swings on REPL 1) The entire review panel at the FDA said “no”… and castigated REPL for not following their advice from 2021 re trial design. So even when Prasad leaves at the end of the month, remember… there is an entire review panel that unanimously said “no”… 2) Me also thinks that getting on talk shows and news casts calling the FDA corrupt and incompetent is prolly not a great way to engender good will if you’re looking for a reversal…🥴☠️ Short term price swing? Sure. Long term game plan? Not so much
0 · Reply
Flyingkitty
Flyingkitty Apr. 24 at 6:34 PM
$REPL LMAO 🤣😂....
0 · Reply
Latest News on REPL
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 22, 2026, 12:56 PM EDT - 2 days ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Apr 13, 2026, 1:44 PM EDT - 11 days ago

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 13, 2026, 11:46 AM EDT - 11 days ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 5:02 PM EDT - 14 days ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

US FDA declines to approve Replimune's drug for advanced skin cancer

Apr 10, 2026, 11:24 AM EDT - 14 days ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Replimune to Present at Two Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 7 weeks ago

Replimune to Present at Two Upcoming Investor Conferences

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 2 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 4 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 5 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR HIMS HTZ LCID NTLA SOC WEN

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 6 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 6 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 6 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 6 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 21, 2025, 7:40 AM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 7 months ago

Replimune Provides Update Following Type A Meeting with FDA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 13, 2025, 10:10 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 5, 2025, 6:54 PM EDT - 8 months ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 8 months ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Replimune Announces Type A Meeting Scheduled with FDA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 4:39 PM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 3:26 PM EDT - 9 months ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 9 months ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 9 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 9 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 9 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 9 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 9 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 9 months ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 10 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 11 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

csliumanila
csliumanila Apr. 25 at 3:49 AM
$REPL "RP1 combined with nivolumab provided deep and durable systemic responses in patients with anti–PD-1–failed melanoma, including those with poor prognostic factors. The safety profile was favorable, with mostly grade 1/2 adverse events." "Tumor-infiltrating lymphocyte therapy (lifileucel) is the only US Food and Drug Administration (FDA)–approved therapy for melanoma in patients previously treated with anti–PD-1 therapy16,17 and provided an objective response rate (ORR) of 31.4%.18 However, nearly all patients experienced grade 3/4 treatment-emergent adverse events,18,19 and the treatment-related mortality rate was 7.5%." https://ascopubs.org/doi/10.1200/JCO-25-01346
0 · Reply
RoyalImperial
RoyalImperial Apr. 24 at 9:43 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $MSS $REPL $BLDP $FFAI ww..11
0 · Reply
GangsterX
GangsterX Apr. 24 at 8:47 PM
$PMVP $GERN $REPL still holding.. 3 biggies
0 · Reply
Spoook
Spoook Apr. 24 at 7:25 PM
$REPL tick…..tick….tick
0 · Reply
US_Bull
US_Bull Apr. 24 at 7:05 PM
$REPL They did the same bs pump after the first CRL remember the liquidity exit where it pumped close to 100% after first CRL and more crying. Retail is left holding the big tute bag
0 · Reply
US_Bull
US_Bull Apr. 24 at 7:02 PM
$REPL Feel bad for those naive retailers who didn't do their DD and listened to the blind bulls living on hopium. As I was saying 1.50$ is coming no time no path forward but to conduct whole new trials after a majorly failed trial design. More dilutions and secondaries to raise money and stay in business. This is one big pipe dream.
1 · Reply
TopCharts
TopCharts Apr. 24 at 6:52 PM
$REPL will be the next outlook therapeutics $2 then ultimately 30 cents. No revenue no approved real product no money.
1 · Reply
cowneck_trader
cowneck_trader Apr. 24 at 6:48 PM
$REPL CEO wamts to waste taxpayer dollars sueing the FDA just so he can get another 6 months of bloated salary. This charlatan needs to have his natualized citizenship revoked!
0 · Reply
USMAgrad
USMAgrad Apr. 24 at 6:43 PM
$REPL Disclaimer: I own 1 share of this stock just for shits-n-grins Just a couple thoughts in the face of the wild price swings on REPL 1) The entire review panel at the FDA said “no”… and castigated REPL for not following their advice from 2021 re trial design. So even when Prasad leaves at the end of the month, remember… there is an entire review panel that unanimously said “no”… 2) Me also thinks that getting on talk shows and news casts calling the FDA corrupt and incompetent is prolly not a great way to engender good will if you’re looking for a reversal…🥴☠️ Short term price swing? Sure. Long term game plan? Not so much
0 · Reply
Flyingkitty
Flyingkitty Apr. 24 at 6:34 PM
$REPL LMAO 🤣😂....
0 · Reply
Fire_Truck
Fire_Truck Apr. 24 at 6:00 PM
$REPL Going back under 2 where it belongs.
1 · Reply
Spoook
Spoook Apr. 24 at 4:44 PM
$REPL Rug Pull coming
0 · Reply
PensionPulse
PensionPulse Apr. 24 at 4:40 PM
$REPL Get back to $1.50, then below $1 where you belong. My message to retail Replimune bagholders, stick a fork in this stock, it's done. Better off selling and investing in $IOVA although I can't say I'm terribly impressed with that stock over the past month.👎😁
0 · Reply
Macdaddy23
Macdaddy23 Apr. 24 at 4:21 PM
$REPL anyone familiar with Hercules Capital? Wondering if they issue notice of default for either Material Adverse Effect or Insolvency (cease ops as normally conducted or terminating substantially all employees) given the company will be illiquid by Q4 even if we assume their quarterly $70M cash burn is cut by 60%.
0 · Reply
IVESTMYWEALTH1
IVESTMYWEALTH1 Apr. 24 at 3:33 PM
$IOVA Totally amazing $1.00 is the separation with $REPL Iovance so undervalued because of consist short pressure. Bullish!
2 · Reply
Rounderssss4
Rounderssss4 Apr. 24 at 3:09 PM
$REPL looks like everyone moving into $OTLK
0 · Reply
IVESTMYWEALTH1
IVESTMYWEALTH1 Apr. 24 at 2:54 PM
$REPL $2.70 could not hold and down it will go.
1 · Reply
ofererez
ofererez Apr. 24 at 2:40 PM
$REPL Bears are trippin …
0 · Reply
Zackpedia
Zackpedia Apr. 24 at 2:33 PM
$REPL 2.58 now YES!
0 · Reply
Zackpedia
Zackpedia Apr. 24 at 2:29 PM
$REPL 2.53 now!
0 · Reply
Zackpedia
Zackpedia Apr. 24 at 2:26 PM
$REPL You could’ve sold when I alerted and bought back at 2.44 now if you wanted, hit Follow and subscribe to get my alerts on time and make money
0 · Reply
locallab
locallab Apr. 24 at 2:18 PM
$REPL back to reality
0 · Reply